Please try another search
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.
Name | Age | Since | Title |
---|---|---|---|
David Power | - | 2017 | Member of Medical Advisory Board |
Sonia Maria Poli | 58 | 2015 | Non Executive Director |
Jonathan J. Hogan | - | 2017 | Member of Medical Advisory Board |
Alessia Fornoni | - | 2017 | Member of Medical Advisory Board |
Hugh Alsop | - | 2017 | Independent Non-Executive Director |
Nina Webster | - | 2018 | CEO, MD & Director |
Daniel Cattran | - | 2017 | Member of Medical Advisory Board |
Clinton Snow | - | 2023 | Non-Executive Director |
Mark Diamond | - | 2023 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review